SCHEMBL14218799

SCHEMBL14218799

CC(C)(C)OC(=O)N1CCCC(c2cc(Nc3ccc(-n4ccnc4)cc3)n3ncc(-c4cn[nH]c4)c3n2)C1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 5/20 0.43
▸ PIK3CD O00329 2/20 0.41
▸ GPR119 Q8TDV5 2/20 0.41
▸ ROCK2 O75116 2/20 0.39
▸ JAK1 P23458 2/20 0.38
▸ PIK3CA P42336 1/20 0.37
▸ TBK1 Q9UHD2 1/20 0.36
▸ JAK2 O60674 2/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ PTK2 Q05397 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CDK4 P11802 1/20 0.35
▸ CCND1 P24385 1/20 0.35
▸ CCND2 P30279 1/20 0.35
▸ CCND3 P30281 1/20 0.35
▸ PRMT5 O14744 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14218632 0.91 CHEK1 (0.45) CHEK1PIK3CDGPR119ROCK2JAK1
SCHEMBL11931565 0.90 CHEK1 (0.52) CHEK1PIK3CDGPR119
SCHEMBL14218631 0.87 CHEK1 (0.43) CHEK1PIK3CDGPR119ROCK2JAK1
SCHEMBL13309478 0.87 GPR119 (0.44) CHEK1PIK3CDGPR119JAK1JAK2
SCHEMBL14219069 0.86 CHEK1 (0.44) CHEK1GPR119ROCK2JAK1PIK3CA
SCHEMBL14232557 0.83 CHEK1 (0.49) CHEK1PIK3CDGPR119ROCK2JAK1
SCHEMBL14219067 0.83 CHEK1 (0.55) CHEK1PIK3CDGPR119ROCK2JAK1
SCHEMBL14218607 0.82 CHEK1 (0.53) CHEK1PIK3CDGPR119ROCK2JAK1
SCHEMBL14232556 0.82 CHEK1 (0.47) CHEK1PIK3CDGPR119ROCK2JAK1
SCHEMBL14219068 0.82 JAK2 (0.43) CHEK1GPR119ROCK2JAK1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008045268-A2 PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS SCHERING CORPORATION (US) 2008-04-17 — — WO disclosed
Send feedback